IRIS
LA MONICA, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.417
AS - Asia 4.974
EU - Europa 4.052
SA - Sud America 686
AF - Africa 285
Continente sconosciuto - Info sul continente non disponibili 205
OC - Oceania 11
Totale 16.630
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.261
SG - Singapore 1.669
CN - Cina 1.392
IT - Italia 1.219
VN - Vietnam 788
IE - Irlanda 574
SE - Svezia 534
BR - Brasile 521
FI - Finlandia 422
DE - Germania 350
HK - Hong Kong 350
BD - Bangladesh 195
FR - Francia 187
ZA - Sudafrica 160
UA - Ucraina 155
NL - Olanda 152
GB - Regno Unito 120
IN - India 115
TR - Turchia 109
CA - Canada 97
RU - Federazione Russa 82
AT - Austria 65
AR - Argentina 62
CI - Costa d'Avorio 62
BE - Belgio 47
JP - Giappone 42
ID - Indonesia 39
PL - Polonia 34
KR - Corea 33
CO - Colombia 32
IQ - Iraq 32
PH - Filippine 29
MX - Messico 27
ES - Italia 26
PK - Pakistan 26
EC - Ecuador 24
TH - Thailandia 20
CZ - Repubblica Ceca 19
SA - Arabia Saudita 18
MA - Marocco 14
IR - Iran 13
UZ - Uzbekistan 13
CL - Cile 12
KE - Kenya 12
VE - Venezuela 12
LT - Lituania 11
HU - Ungheria 9
MY - Malesia 9
TW - Taiwan 8
AU - Australia 7
JO - Giordania 7
PY - Paraguay 7
SY - Repubblica araba siriana 7
TN - Tunisia 7
AL - Albania 6
BO - Bolivia 6
DZ - Algeria 6
LU - Lussemburgo 6
NP - Nepal 6
PS - Palestinian Territory 6
RO - Romania 6
UY - Uruguay 6
AZ - Azerbaigian 5
EG - Egitto 5
HN - Honduras 5
JM - Giamaica 5
KG - Kirghizistan 5
MD - Moldavia 5
OM - Oman 5
CH - Svizzera 4
GT - Guatemala 4
IL - Israele 4
LB - Libano 4
NZ - Nuova Zelanda 4
PA - Panama 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
CG - Congo 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GE - Georgia 3
KZ - Kazakistan 3
NI - Nicaragua 3
RS - Serbia 3
SI - Slovenia 3
BB - Barbados 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
EU - Europa 2
GA - Gabon 2
HR - Croazia 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LY - Libia 2
QA - Qatar 2
SN - Senegal 2
TJ - Tagikistan 2
TT - Trinidad e Tobago 2
Totale 16.405
Salva come PNG Salva come JPEG
Città #
Singapore 884
Ashburn 640
Dallas 623
San Jose 613
Dublin 573
Chandler 499
Santa Clara 418
Parma 332
Hong Kong 324
Beijing 321
Ann Arbor 314
Council Bluffs 268
Ho Chi Minh City 232
Boardman 188
Jacksonville 188
Dearborn 167
Hanoi 156
Los Angeles 155
Johannesburg 152
New York 149
Chicago 121
Nanjing 119
Shanghai 116
Munich 107
Lauterbourg 98
Milan 92
Princeton 89
Hefei 87
Izmir 82
Abidjan 62
Bologna 59
Wilmington 57
Bremen 56
Buffalo 56
San Mateo 55
Rome 52
Nanchang 51
São Paulo 51
Vienna 50
Kunming 48
Helsinki 47
Shenyang 47
Toronto 41
Haiphong 40
Modena 38
Tianjin 38
Marseille 35
Brussels 30
Da Nang 30
Seattle 30
Columbus 29
Des Moines 29
Guangzhou 29
Hebei 29
Jinan 29
Jakarta 28
Moscow 28
Phoenix 26
Turku 26
Warsaw 26
London 24
Tokyo 24
Denver 23
Frankfurt am Main 23
Pune 23
Reggio Emilia 23
The Dalles 23
Houston 22
Changsha 21
Grafing 21
Nuremberg 21
Seoul 21
Woodbridge 21
Amsterdam 20
Brooklyn 20
Montreal 20
Rio de Janeiro 20
Levanto 19
Norwalk 19
Redmond 19
Jiaxing 17
Stockholm 17
Atlanta 15
Fremont 15
Orem 15
Manchester 14
Boston 13
Brasília 13
Brescia 13
Chennai 13
Hải Dương 13
Leawood 13
Bari 12
Belo Horizonte 12
Florence 12
Naples 12
San Francisco 12
Tashkent 12
Verona 12
Wayne 12
Totale 10.053
Salva come PNG Salva come JPEG
Nome #
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 305
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 287
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 258
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 258
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 253
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 225
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 222
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 219
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 216
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 214
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 214
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 213
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 212
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 208
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 202
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 201
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 199
Characterization of gefitinib uptake in NSCLC cell lines 197
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 197
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 195
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 189
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 188
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 187
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 187
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 185
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 182
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 182
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 180
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 179
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 178
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 176
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 176
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 174
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 170
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 170
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 170
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 166
Interaction between occupational radon exposure and tobacco smoke: a systematic review 165
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 165
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 163
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 163
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 162
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 162
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 161
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 161
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 155
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 153
Synergistic activity of letrozole and sorafenib on breast cancer cells 153
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 152
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 150
Physico-chemical characterization and biological evaluation of two fibroin materials 150
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 150
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 149
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 149
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 145
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 144
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 143
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 140
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 139
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 139
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 138
Functional and morphological characterisation of human colonoid-derived monolayers under inflammatory conditions 137
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 136
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 135
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 134
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 134
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 133
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 128
null 126
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 125
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 124
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 124
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 122
Successful regrowth of retinal neurons when cultured interfaced to carbon nanotube platforms 122
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 121
Osteopontin is produced by human multiple myeloma cells 120
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry 120
Multiple myeloma patient with unusual extramedullary involvement 116
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 116
Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage 116
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 115
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 113
Multiple myeloma patient with unusual extramedullary involvement 111
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells 110
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 109
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 108
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 108
Generation and characterization of a new preclinical mouse model of egfr-driven lung cancer with met-induced osimertinib resistance 106
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 106
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 105
Targeting FGFR1 pathway in squamous cell lung cancer 103
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 100
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 100
Optimizing EGFR inhibitor treatment in non small cell lung cancer 100
Circulating neural growth factor in pancreatic cancer adenocarcinoma 99
Evaluation of gefitinib maintenance in an EGFR-mutant NSCLC cell line with acquired resistance 97
Overcoming resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer cell lines 97
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 94
RANKL is critically involved in the physiopathology of multiple myeloma 94
Preclinical study assessing effects of gefitinib continuation after development of gefitinib resistance in NSCLC with activating EGFR mutations 92
Totale 15.641
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.972
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.972
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022523 0 0 52 41 20 25 88 50 31 22 40 154
2022/20232.208 211 234 150 141 197 244 45 142 687 17 101 39
2023/20241.003 35 73 34 47 81 185 85 81 44 55 105 178
2024/20252.898 137 136 185 197 279 281 204 144 338 241 261 495
2025/20266.492 517 583 853 585 815 354 690 200 893 450 377 175
2026/2027779 240 364 175 0 0 0 0 0 0 0 0 0
Totale 16.630